Asana reports Phase I/II data for SYK/JAK inhibitor ASN002 to treat cancer

Asana BioSciences LLC (Lawrenceville, N.J.) reported data from 36 patients with non-Hodgkin’s lymphoma (NHL) or advanced solid tumors in the dose-escalation Phase I portion of

Read the full 257 word article

User Sign In